Core Points - Anteris Technologies Global Corp. has adjourned its Special Meeting of Stockholders due to lack of quorum, rescheduling it for September 29, 2025 [1][2] - The Company encourages stockholders to vote on proposals outlined in the definitive Proxy Statement filed with the SEC on August 18, 2025 [2][6] - Anteris is focused on developing innovative medical devices for heart function restoration, with its lead product being the DurAVR® Transcatheter Heart Valve [7][8] Voting Details - Stockholders who have already voted do not need to take further action as their votes will remain counted [3] - New votes can be submitted via the Proxy Statement, with deadlines for Internet and telephone submissions set for September 28, 2025, and for mail submissions by September 26, 2025 [4] - CDI holders must direct CDN to vote by September 25, 2025, to ensure their votes are counted [5] Company Overview - Anteris Technologies is a global structural heart company with a significant presence in both Australia and the USA [7] - The DurAVR® Transcatheter Heart Valve is designed to treat aortic stenosis and is the first biomimetic valve, utilizing Anteris' patented ADAPT® tissue technology [8]